Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 97

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 97
---
 securities exchange on which our shares are listed in the future. The policy is administered by our Board of Directors or, if so
designated by the Board of Directors, the Compensation Committee. Any determinations made by the Board shall be final and binding on
all affected individuals.

The individuals covered by
this policy (the “Covered Officers”) are any current or former employee who is or was identified as our president, principal
financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president in charge
of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a significant
policy-making function, or any other person (including any executive officer of our subsidiaries or affiliates) who performs similar
significant policy-making functions for us.

The policy covers our recoupment
of “Incentive-Based Compensation” (as defined in the policy) received by a person after beginning service as a Covered Executive
and who served as a Covered Officer at any time during the performance period for that Incentive Compensation. In the event we are required
to prepare an accounting restatement, the policy requires us to recover, reasonably promptly, any excess incentive compensation (as determined
by our Board of Directors or Compensation Committee) received by any Covered Officer during the three completed fiscal years immediately
preceding the date on which we are required to prepare such accounting restatement. The foregoing description of our Compensation Recovery
Policy does not purport to be complete and is qualified in its entirety by the terms and conditions of such policy, a copy of which is
filed as an exhibit to the Company’s Form 10-K filed with the SEC for the fiscal year ended December 31, 2024.

| 53 |

<div align='center'>EXECUTIVE COMPENSATION</div>

= Director Compensation

We did not provide any cash compensation to any of our directors during the year ended December 31, 2024 in their capacity as directors. However, on April 25, 2024, Matthew Del Giudice, Edward MacPherson, and Denil Shekhat were granted an option to purchase up to 50,000 shares of our common stock under the 2022 Omnibus Plan for joining the board. Additionally, on December 6, 2024, each non-employee director was granted an additional option to purchase up to 25,000 shares of our common stock under the 2022 Omn